Prevalence of metabolic syndrome in rheumatoid arthritis patients from Northeastern Brazil: Association with disease activity

Gomes, Kirla Wagner Poti; Luz, A.J.P.; Felipe, Marcos; Beltrão, Lara Amorim; Sampaio, André Xenofonte Cartaxo; Rodrigues, Carlos Ewerton Maia

doi:10.1080/14397595.2017.1316813

Cited by 19 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is supported by a recent meta-analysis on MetS in RA patients which revealed increased WC to be the most frequent component of the syndrome, matching the results of several others [33][34][35]. These findings point to the [30]. The finding of BMI-defined obesity in 26.9% of our patients is compatible with the literature.…”

Section: Discussionsupporting

confidence: 92%

“…Most of our patients were overweight or obese women with long-standing RA and moderate disease activity, indicating a relatively serious condition with high risk of cardiovascular disease. Relevantly, in a recent study based on a cohort of 338 RA patients, MetS was highly prevalent (51.3%, one of the highest prevalences reported in the literature) and associated with disease activity [30].…”

Section: Discussionmentioning

confidence: 81%

See 1 more Smart Citation

High prevalence of obesity in rheumatoid arthritis patients: association with disease activity, hypertension, dyslipidemia and diabetes, a multi-center study

et al. 2019

Self Cite

View full text Add to dashboard Cite

Introduction: Rheumatoid arthritis (RA) is a well-documented independent risk factor for cardiovascular disease. Obesity may provide an additional link between inflammation and accelerated atherosclerosis in RA. Objective: To evaluate the association between obesity and disease parameters and cardiovascular risk factors in RA patients. Method: Cross-sectional study of a cohort of RA patients from three Brazilian teaching hospitals. Information on demographics, clinical parameters and the presence of cardiovascular risk factors was collected. Blood pressure, weight, height and waist circumference (WC) were measured during the first consultation. Laboratory data were retrieved from medical records. Obesity was defined according to the NCEP/ATPIII and IDF guidelines. The prevalence of obesity was determined cross-sectionally. Disease activity was evaluated using the DAS28 system (remission < 2.6; low 2.6-3.1; moderate 3.2-5.0; high > 5.1). Results: The sample consisted of 791 RA patients aged 54.7 ± 12.0 years, of whom 86.9% were women and 59.9% were Caucasian. The mean disease duration was 12.8 ± 8.9 years. Three quarters were rheumatoid factor-positive, the mean body mass index (BMI) was 27.1 ± 4.9, and the mean WC was 93.5 ± 12.5 cm. The observed risk factors included dyslipidemia (34.3%), type-2 diabetes (15%), hypertension (49.2%) and family history of premature cardiovascular disease (16.5%). BMIdefined obesity was highly prevalent (26.9%) and associated with age, hypertension and dyslipidemia. Increased WC was associated with diabetes, hypertension, dyslipidemia and disease activity. Conclusion: Obesity was highly prevalent in RA patients and associated with disease activity.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 81%

High prevalence of obesity in rheumatoid arthritis patients: association with disease activity, hypertension, dyslipidemia and diabetes, a multi-center study

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…The country of publication differed between the included studies. There were six studies conducted among RA patients in North America (the USA) [ 16 , 19 , 33 , 34 , 37 , 40 ], two studies in Latin America (Mexico, Colombia, and Brazil) [ 12 , 14 ], two in Asia Pacific (Australia and Taiwan) [ 25 , 35 ] and six in Europe (France, Sweden and Netherlands) [ 11 , 15 , 17 , 36 , 38 , 39 ].…”

Section: Resultsmentioning

confidence: 99%

“…Additionally, the mean age of RA patients ranged between 49 [ 35 ] and 67 years [ 38 ]. Patients included in this systematic review had established RA (mean range of RA duration was 2.2±8.7 [ 36 ] and 14.4±12.4 [ 37 ] years). Although early RA (mean RA duration 3.3 months) was examined in one of studies [ 11 ], data were obtained during the follow-up period (5 years), which indicates that patients had established RA.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: A systematic review and meta-analysis

Baghdadi

2020

PLoS ONE

View full text Add to dashboard Cite

Background The high risk of cardiovascular disease is well recognized in rheumatoid arthritis. Type 2 diabetes also attributes to this increase in risk. Rheumatoid arthritis is a chronic inflammatory condition, which aggravates insulin resistance, placing the patients at a higher risk of type 2 diabetes and subsequent cardiovascular outcomes. Methotrexate treatment, as a gold standard anti-inflammatory drug in the treatment of rheumatoid arthritis has shown beneficial effects on cardiovascular health. However, its impact on type 2 diabetes is still unknown. Objective To assess the strength of the association between exposure to methotrexate and the rate of development of type 2 diabetes in rheumatoid arthritis patients. Methods All rheumatoid arthritis studies reporting the use of methotrexate as an exposure and type 2 diabetes as an outcome were searched until March 2020 using MEDLINE, Cochrane and Scopus databases. Studies were included if the diagnosis of rheumatoid arthritis was made according to current guidelines or by a rheumatologist, and if there was information about methotrexate exposure and the type 2 diabetes outcome. The author and an independent assessor evaluated the articles for eligibility. Meta-analyses combined relative risk estimates from each study where raw counts were available. Results Sixteen studies reporting sufficient data for inclusion in the meta-analyses were identified. Methotrexate showed a promising effect on the risk of type 2 diabetes as this risk decreased in rheumatoid arthritis patients using methotrexate (Relative risk 0.48, 95% CI 0.16, 1.43).

show abstract

Athrogenic indexes: Useful markers for predicting metabolic syndrome in axial spondyloarthritis

Slouma

Ali²,

Kharrat³

et al. 2022

Clínica e Investigación en Arteriosclerosis (English Edition)

View full text Add to dashboard Cite

Prevalence of metabolic syndrome in rheumatoid arthritis patients from Northeastern Brazil: Association with disease activity

Cited by 19 publications

References 18 publications

High prevalence of obesity in rheumatoid arthritis patients: association with disease activity, hypertension, dyslipidemia and diabetes, a multi-center study

High prevalence of obesity in rheumatoid arthritis patients: association with disease activity, hypertension, dyslipidemia and diabetes, a multi-center study

Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: A systematic review and meta-analysis

Athrogenic indexes: Useful markers for predicting metabolic syndrome in axial spondyloarthritis

Contact Info

Product

Resources

About